Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF V600
BRAF V600 - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- In a Phase Ib Dose-Escalation Study of Encorafenib, Cetuximab and Alpelisib, Twenty-eight patients with refractory BRAFV600 mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab) with a PI3Kα inhibitor (alpelisib). Confirmed overall response rates of 18% were observed and median progression-free survival was 4.2 months
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6047
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/17
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Encorafenib,Alpelisib,Cetuximab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 28363909
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Alpelisib | Sensitivity | true |
| Encorafenib | Sensitivity | true |
| Cetuximab | Sensitivity | true |